At PromiseCare Medical Group in Hemet, California, Transurethral Microwave Thermotherapy (TUMT) is a notable treatment option for patients with benign prostatic hyperplasia (BPH). This 60-minute procedure is minimally invasive and utilizes microwave energy to target and destroy obstructive prostate tissue.
Suitable candidates typically have moderate to severe BPH symptoms and a small to moderate prostate size, with a preference for non-invasive treatments. The procedure aims to improve urinary flow and overall quality of life.
However, TUMT is associated with risks of intensified urinary symptoms and potential complications. PromiseCare Medical Group’s medical professionals can help patients understand what to expect, including preparation, procedure, and possible outcomes.
PromiseCare Medical Group’s approach evaluates individual patient needs, ensuring a comprehensive exploration of TUMT as a viable treatment option.
Overview
Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
Effective treatment options are available for men experiencing the bothersome symptoms of BPH. Transurethral Microwave Thermotherapy (TUMT) is a minimally invasive outpatient procedure designed to relieve urinary symptoms caused by an enlarged prostate. This treatment utilizes microwave energy to eliminate excess prostate tissue that interferes with urine flow, offering substantial relief for men suffering from moderate to severe lower urinary tract symptoms.
The 60-minute procedure involves inserting a catheter with a microwave antenna through the urethra. The catheter delivers controlled microwave energy, heating the prostate tissue to approximately 110°F. This process achieves coagulative necrosis while preserving surrounding structures.
Performed under local anesthesia, TUMT allows patients to return home shortly after treatment. Research indicates that TUMT leads to significant improvements in urinary symptoms and flow rates, with notable decreases in symptom scores within six months post-procedure.
As a minimally invasive procedure, TUMT offers a promising solution for men seeking effective BPH treatment without sacrificing comfort or convenience.
Types
Exploring the various types of Transurethral Microwave Thermotherapy (TUMT) is essential for understanding the range of treatment options available for Benign Prostatic Hyperplasia (BPH).
TUMT is primarily classified into two types based on the energy source used: conventional microwave thermotherapy and high-intensity focused microwave therapy.
Variations in TUMT procedures exist, including using different catheter designs and configurations, which can affect treatment outcomes and patient comfort.
Key differences:
- Conventional microwave thermotherapy uses a fixed microwave frequency
- High-intensity focused microwave therapy employs a more concentrated energy delivery approach
- Different protocols exist for TUMT, with variations in energy levels and treatment duration
- TUMT can be performed as a single-session treatment or as part of a series of treatments
The choice of TUMT type and protocol is influenced by factors such as prostate size, symptom severity, and patient health status.
The choice of TUMT type depends on factors such as prostate size, symptom severity, and patient health status.
Understanding the different types of TUMT allows for informed decision-making about treatment options.
Why it’s done
Transurethral Microwave Thermotherapy (TUMT) is a treatment option for Benign Prostatic Hyperplasia (BPH) that aims to alleviate lower urinary tract symptoms (LUTS) such as urinary frequency, weak flow, or obstruction.
This minimally invasive procedure uses microwave energy to destroy excess prostate tissue, reducing urinary obstruction and improving urine flow.
The decision to undergo TUMT is often driven by the need to address these symptoms and improve quality of life.
Who it’s for
Determining whether Transurethral Microwave Thermotherapy (TUMT) is the proper treatment for benign prostatic hyperplasia (BPH) symptoms requires careful evaluation of individual health situations.
Candidates for TUMT typically experience moderate to severe lower urinary tract symptoms (LUTS) and haven’t found relief from medical therapy.
Key factors to evaluate include:
- Prostate size, which should be small to moderate, is assessed through imaging and health history evaluations.
- The desire for minimally invasive treatments to improve urinary flow and quality of life.
- The absence of active urinary infections, prostate cancer, or a history of transurethral resection of the prostate (TURP) or severe pelvic trauma.
- Not having a pacemaker or significant pain responses that may complicate the procedure.
- Seeking an alternative to more invasive surgical methods to address BPH symptoms.
If these factors align with an individual’s situation, TUMT may be a viable option.
Careful evaluation of health and discussion of options can inform the decision about whether TUMT is the right choice for treating BPH symptoms.
Risks
Uncertainty often accompanies medical procedures, particularly Transurethral Microwave Thermotherapy (TUMT). When treating an enlarged prostate, it’s essential to weigh the potential risks against the benefits. Complications, such as worsened urinary symptoms following the procedure, may occur, potentially necessitating further treatment or catheterization.
A significant concern is the risk of urinary retention requiring catheterization, which affects approximately 11% of patients after TUMT. Additionally, about 13% of patients develop urinary tract infections (UTIs), often due to prolonged catheter use.
Acute incontinence is another potential risk, affecting around 3% of patients and highlighting the possibility of temporary urinary control issues. While serious complications are rare, damage to the penis and urethra can occur, and regulatory agencies have issued warnings about these risks.
Careful consideration of these risks is crucial, and discussing concerns with a healthcare provider can help inform the decision to undergo TUMT. Understanding the potential complications can help navigate the treatment process and manage expectations effectively.
How you prepare
Preparing for Transurethral Microwave Thermotherapy requires several steps to ensure a successful and smooth experience.
Pre-procedure preparation is crucial for this outpatient treatment. The following steps should be taken:
- Antibiotics may be prescribed to minimize the risk of urinary tract infections and should be taken as directed.
- Transportation home after the procedure should be arranged, as sedation may be used, making it unsafe to drive.
- Specific pre-procedure instructions should be followed, including potential dietary restrictions or medication adjustments.
- A local anesthetic will be applied to the prostate area during the procedure, and IV sedation may also be used to enhance comfort.
- It’s best to avoid strenuous activities for 3 to 5 days during the recovery period.
What you can expect
What to Expect During and After Transurethral Microwave Thermotherapy
Transurethral Microwave Thermotherapy (TUMT) is usually conducted on an outpatient basis and takes about 60 minutes. Patients typically recover from sedation by the end of the day, enabling them to return home afterward.
During the recovery period, mild discomfort, blood in the urine, or temporary difficulty with urination may be experienced. Some patients may require a urinary catheter for a short time.
Normal activities can usually be resumed within 1 to 2 days, but driving should be avoided for at least 24 hours after treatment.
Follow-up care is necessary to monitor the recovery process. If severe abdominal pain or high fever occurs, seek immediate medical attention.
Avoid sexual activity for 1 to 2 weeks, depending on individual recovery. Symptoms during the recovery period are typical but should improve over time.
Results
Transurethral Microwave Thermotherapy (TUMT) outcomes are a crucial aspect of the treatment process for patients with benign prostatic hyperplasia (BPH), directly impacting their quality of life. Following TUMT, notable improvements can be expected in lower urinary tract symptoms.
The average symptom score decreases by 11 points at 6 months post-treatment, indicating effective symptom relief for BPH patients. Mean maximum urine flow rates improve from 7.3 mL/s to 14.5 mL/s at 6 months after TUMT, with results remaining stable at 12 months.
The retreatment rate for TUMT stands at about 9.9%, significantly higher than the approximately 2.3% retreatment rate seen with other BPH treatments, such as Transurethral Resection of the Prostate (TURP).
Complications after TUMT include urinary retention in about 11% of patients and urinary tract infections in approximately 13%.
Patient satisfaction with sexual life post-TUMT is notably higher at 55% compared to other treatments. However, patient satisfaction with urinary flow rates post-TUMT is lower at 27% compared to other therapies like TURP, which is around 74%.
These outcomes should be carefully considered when evaluating TUMT as a treatment option for BPH.